Biomaterials Research · 2024 · 10 citations · 37 references
MedicineOncologyPharmacologyChemotherapyDrug DeliveryImmunotherapyCancer ImmunotherapyCancer NanomedicineLipid-based NanoparticlesNanocarriers For TherapeuticsNanomedicineTumor Microenvironment ModulationChemotherapy-induced Immunogenic Cell DeathImmunogenic Cell Death InductionInnate Antitumor ImmunityLipid Nanoparticle Delivery SystemsNanoparticle-based ImmunotherapySting PathwaySynergistic Immunotherapy MechanismsTumor-targeted Drug Delivery
Immunotherapy shows great therapeutic potential for long-term protection against tumor relapse and metastasis. Innate immune sensors, such as cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING), dissolve DNA and induce type I interferon. Through activation of the cGAS/STING pathway, chemotherapy drugs and reversine (REV) may provide synergetic anti-tumor effects. Here, we prepared drug-loaded cell membrane hybrid lipid nanovesicles (LEVs) (designated LEV@DOX@REV) by fusion of cell membranes, phospholipids, doxorubicin (DOX), and REV, to realize accurate delivery to tumors and chemo-immunotherapy. The cell membranes of LEVs confer "homing" abilities. DOX can induce immunogenic cell death as a result of its specific immunomodulatory effects, which promotes the maturation of immune cells and improves the microenvironment of the immune system. REV is proven to efficiently activate cGAS/STING signaling, thereby enhancing the immune system. The antitumor efficacy of LEV@DOX@REV was evaluated in a 4T1 subcutaneous tumor xenograft model, a distant metastatic tumor model, and a liver metastatic tumor model. LEV@DOX@REV facilitated the infiltration of cytotoxic T lymphocytes within tumors, increased the secretion of proinflammatory cytokines, and modified the tumor microenvironment. In conclusion, LEV@DOX@REV displayed favorable antitumor effects and extended the survival of tumor-bearing mice. We therefore successfully developed nanoparticles capable of enhancing immune activation that have potential therapeutic applications for cancer immunotherapy.
37
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2022 · 18.2K citations · Full text
Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery
Ronnie H. Fang, Che‐Ming Jack Hu, Brian T. Luk et al. · Nano Letters · 2014 · 1.5K citations · Full text
Pharmacy, Immunology, Pharmaceutics +17
Cytoplasmic chromatin triggers inflammation in senescence and cancer
Zhixun Dou, Kanad Ghosh, Maria Grazia Vizioli et al. · Nature · 2017 · 1.3K citations · Full text
Su Chul Jang, Oh Youn Kim, Chang Min Yoon et al. · ACS Nano · 2013 · 1K citations
Pharmacy, Oncology, Pharmacology +17
Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy
Tuying Yong, Xiaoqiong Zhang, Nana Bie et al. · Nature Communications · 2019 · 809 citations · Full text
Pharmacy, Oncology, Pharmacology +17